Trial reportCNS drugs2017
Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial.
Trial report in CNS drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00151801 (Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Instruments measuring change in cognitive function in multiple sclerosis: A systematic review.Brain and behavior · 2023Pooled it
- Potential Protective Role of Pregnancy and Breastfeeding in Delaying Onset Symptoms Related to Multiple Sclerosis.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.CNS drugs · 2020Pooled it
- Understanding the Role of Hypothalamic-Pituitary-Gonadal Axis in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.Biomedicines · 2026Review
- Neurologic Care for Transgender and Gender-Diverse People: A Review of Current Evidence and Clinical Implications.Neurology. Clinical practice · 2024Review
- The effect of interferon beta on quality of life in patients with multiple sclerosis: A systematic review and meta-analysis study.Current journal of neurology · 2024Review
- Sex hormone therapy in Multiple Sclerosis: A systematic review of randomized clinical trials.Journal of central nervous system disease · 2024Review
- Gender differences in the burden of multiple sclerosis in China from 1990 to 2019 and its 25-year projection: An analysis of the Global Burden of Diseases Study.Health science reports · 2023Article
- Sex Hormones as Key Modulators of the Immune Response in Multiple Sclerosis: A Review.Biomedicines · 2022Review
- Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: How it influences clinical course, MRI parameters and prognosis.Frontiers in immunology · 2022Review
- Effects of the Menstrual Cycle on Neurological Disorders.Current neurology and neuroscience reports · 2021Review
- Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review.Frontiers in neurology · 2021Review
- The effect of sex on multiple sclerosis risk and disease progression.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Review
- Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors.PloS one · 2019Article
- Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Article
- Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCognitive impairment is a disabling symptom in multiple sclerosis (MS). While its management remains challenging, beneficial effects on cognition of interferon beta (IFN-β) have been reported and a positive effect from estroprogestins has been hypothesised, suggesting that the combination of the two medications in women with MS could offer a promising treatment strategy.
objectivesWe investigated whether a combination of estroprogestins and IFN-β can improve cognition in women with MS.
methodsWomen with relapsing-remitting (RR) MS were randomly assigned (1:1:1) to receive subcutaneous IFN-β-1a (Rebif
resultsAt baseline, there was no difference in the proportion of cognitively impaired patients. At month 24, the proportion of patients with cognitive impairment was lower in group 3 (34.8%) than in group 1 (47.6%) (p = 0.03). The risk of developing cognitive impairment over 24 months was lower in group 3 (p = 0.02). Mood and fatigue scores were comparable across the groups over time at both time points. However, at month 24, group 3 showed worsening on the sexual function subscale of the 54-item MS quality-of-life questionnaire (p = 0.03).
conclusionsThis study suggests that the combination of high-dose estroprogestins and IFN-β may have positive effects on cognition. However, the effect of this treatment on sexual function requires caution to be exercised. Protocol Number NCT00151801, registered in ClinicalTrials.gov.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.